Prognostic impact of cardiovascular polypharmacy on octogenarians with heart failure with preserved ejection fraction

被引:2
|
作者
Nishino, Masami [1 ]
Egami, Yasuyuki [1 ]
Kawanami, Shodai [1 ]
Sugae, Hiroki [1 ]
Ukita, Kohei [1 ]
Kawamura, Akito [1 ,6 ]
Nakamura, Hitoshi [1 ]
Yasumoto, Koji [1 ]
Tsuda, Masaki [1 ]
Okamoto, Naotaka [1 ]
Matsunaga-Lee, Yasuharu [1 ]
Yano, Masamichi [1 ]
Tanouchi, Jun [1 ]
Yamada, Takahisa [2 ,5 ]
Yasumura, Yoshio [3 ]
Seo, Masahiro [2 ]
Tamaki, Shunsuke [4 ]
Hayashi, Takaharu
Nakagawa, Akito [3 ]
Nakagawa, Yusuke [7 ]
Sotomi, Yohei [8 ]
Nakatani, Daisaku [8 ]
Hikoso, Shungo [8 ]
Sakata, Yasushi [8 ]
机构
[1] Osaka Rosai Hosp, Div Cardiol, 3-1179 Nagasonecho,Kita Ku, Sakai, Osaka 5918025, Japan
[2] Osaka Gen Med Ctr, Div Cardiol, 3-1-56 Mandaihigashi,Sumiyoshi Ku, Osaka 5588558, Japan
[3] Amagasaki Chuo Hosp, Div Cardiol, 1-12-1 Shioe, Amagasaki, Hyogo 6610976, Japan
[4] Rinku Gen Med Ctr, Div Cardiol, 2-23 Rinkuoraikita, Izumisano, Osaka 5980048, Japan
[5] Osaka Police Hosp, Cardiovasc Div, 10-31 Kitayamacho,Tennoji Ku, Osaka 5430035, Japan
[6] Osaka Univ, Dept Med Informat, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[7] Kawanishi City Med Ctr, Div Cardiol, 1-4-1 Hiuchi, Kawanishi, Hyogo 6660017, Japan
[8] Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
关键词
Polypharmacy; Heart failure with preserved ejection fraction; Diuretics; Octogenarian; MEDICATION REGIMEN COMPLEXITY; EVENTS; HOSPITALIZATION; ASSOCIATION; GUIDELINES; DIAGNOSIS; SOCIETY; ADULTS; ESC;
D O I
10.1016/j.ijcard.2023.02.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Backgrounds: Drug treatments of heart failure with preserved ejection fraction (HFpEF) have a little clinical benefit, but cardiovascular polypharmacy (CP) trend is observed in elderly HFpEF. We investigated the impact of CP on octogenarian with HFpEF.Methods: We examined 783 consecutive octogenarians (>= 80 years) enrolled in the PURSUIT-HFpEF registry. We defined medications for hypertension, dyslipidemia, heart failure (HF), coronary artery disease, stroke, pe-ripheral artery disease, and atrial fibrillation as cardiovascular medications (CM). In this study, we defined CP as >= 5 CM. We investigated whether CP was correlated with the composite end point (CE) of all-cause mortality and HF rehospitalization. Results: The proportion with CP was 51.9% (n = 406). Background characteristics correlated with CP were frailty, history of coronary artery disease, atrial fibrillation and left atrial dimension. Multivariable Cox proportional hazards analysis showed CP was significantly and independently correlated with CE (hazard ratio (HR): 1.31; 95% confidence Interval (CI): 1.01-1.70) in addition to age, clinical frailty scale, history of HF admission and N-terminal pro brain natriuretic peptide. Kaplan-Meier curve analysis showed that, compared with the non-CP group, the CP group had significantly higher risk of CE and HF (HR: 1.27; 95%CI: 1.04-1.56; P = 0.02 and HR: 1.46; 95%CI: 1.13-1.88; P < 0.01, respectively), but not any-cause death. In addition, diuretics were correlated with CE (HR: 1.61; 95%CI: 1.17-2.22; P < 0.01), but antithrombotic drugs and HFpEF medications were not.Conclusions: CP at discharge is a prognostic factor driven by HF rehospitalization in octogenarians with HFpEF. In these patients, diuretics may be correlated with the prognosis.
引用
收藏
页码:55 / 63
页数:9
相关论文
共 50 条
  • [1] Reply to "Prognostic impact of cardiovascular polypharmacy on octogenarians with heart failure with preserved ejection fraction"
    Nishino, Masami
    Egami, Yasuyuki
    Yamada, Takahisa
    Yasumura, Yoshio
    Nakatani, Daisaku
    Hikoso, Shungo
    Sakata, Yasushi
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 383 : 61 - 61
  • [2] Prognostic Impact of Statins in Heart Failure with Preserved Ejection Fraction
    Ortega-Hernandez, Samanta
    Gonzalez-Sosa, Sonia
    Conde-Martel, Alicia
    Trullas, Joan Carles
    Llacer, Pau
    Perez-Silvestre, Jose
    Arevalo-Lorido, Jose Carlos
    Casado, Jesus
    Formiga, Francesc
    Manzano, Luis
    Lorenzo-Villalba, Noel
    Montero-Perez-Barquero, Manuel
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (19)
  • [3] Pathophysiology of Heart Failure with Preserved Ejection Fraction
    Youn, Jong-Chan
    Ahn, Yuran
    Jung, Hae Ok
    HEART FAILURE CLINICS, 2021, 17 (03) : 327 - 335
  • [4] Prognostic impact of heart failure with preserved ejection fraction in patients with mild symptoms
    Jung, P.
    Huber, T.
    Mueller, M.
    Koenig, A.
    Kroetz, F.
    Sohn, H. -Y.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (14) : 706 - 710
  • [5] Impact of readmissions on octogenarians with heart failure with preserved ejection fraction: PURSUIT-HFpEF registry
    Nishino, Masami
    Yano, Masamichi
    Ukita, Kohei
    Kawamura, Akito
    Nakamura, Hitoshi
    Matsuhiro, Yutaka
    Yasumoto, Koji
    Tsuda, Masaki
    Okamoto, Naotaka
    Tanaka, Akihiro
    Matsunaga-Lee, Yasuharu
    Egami, Yasuyuki
    Shutta, Ryu
    Tanouchi, Jun
    Yamada, Takahisa
    Yasumura, Yoshio
    Tamaki, Shunsuke
    Hayashi, Takaharu
    Nakagawa, Akito
    Nakagawa, Yusuke
    Suna, Shinichiro
    Nakatani, Daisaku
    Hikoso, Shungo
    Sakata, Yasushi
    ESC HEART FAILURE, 2021, 8 (03): : 2120 - 2132
  • [6] Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
    Lofstrom, Ulrika
    Hage, Camilla
    Savarese, Gianluigi
    Donal, Erwan
    Daubert, Jean-Claude
    Lund, Lars H.
    Linde, Cecilia
    ESC HEART FAILURE, 2019, 6 (04): : 830 - 839
  • [7] Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
    Lin, Tin-Kwang
    Hsu, Bo-Cheng
    Li, Yi-Da
    Chen, Chi-Hsien
    Lin, Jiunn-Wen
    Chien, Chen-Yu
    Weng, Chia-Ying
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (12):
  • [8] Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
    Lopez-Vilella, Raquel
    Lozano-Edo, Silvia
    Arenas Martin, Patricia
    Jover-Pastor, Pablo
    Ezzitouny, Meryem
    Sorolla Romero, Jose
    Calvo Asensio, Maria
    Martinez-Sole, Julia
    Guerrero Cervera, Borja
    Sanchez Martinez, Jose Carlos
    Donoso Trenado, Victor
    Sanchez-Lazaro, Ignacio
    Martinez Dolz, Luis
    Almenar Bonet, Luis
    ESC HEART FAILURE, 2022, 9 (01): : 133 - 145
  • [9] Ivabradine for Treatment of Heart Failure With Preserved Ejection Fraction
    Babushkina, G. V.
    Shaykhlislamova, G. I.
    KARDIOLOGIYA, 2020, 60 (10) : 33 - 37
  • [10] Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
    Suzuki, Sho
    Motoki, Hirohiko
    Kanzaki, Yusuke
    Maruyama, Takuya
    Hashizume, Naoto
    Kozuka, Ayako
    Yahikozawa, Kumiko
    Kuwahara, Koichiro
    ESC HEART FAILURE, 2020, 7 (05): : 2752 - 2761